Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of “Buy” from Analysts

Bioventus Inc. (NASDAQ:BVS) has received an average recommendation of “Buy” from the six brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $14.20.

BVS has been the topic of a number of recent analyst reports. Barrington Research reissued an “outperform” rating and issued a $14.00 price objective on shares of Bioventus in a research note on Friday, May 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Canaccord Genuity Group restated a “buy” rating and set a $15.00 target price on shares of Bioventus in a research report on Tuesday, June 16th. CJS Securities assumed coverage on Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 target price for the company. Finally, Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th.

Bioventus Price Performance

Bioventus stock opened at $9.78 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The firm has a market cap of $817.02 million, a P/E ratio of 23.85, a P/E/G ratio of 1.26 and a beta of 0.67. The business’s fifty day moving average is $9.55 and its two-hundred day moving average is $8.74. Bioventus has a 52 week low of $5.81 and a 52 week high of $11.25.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. The company had revenue of $132.09 million for the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities research analysts forecast that Bioventus will post 0.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bioventus

Institutional investors and hedge funds have recently made changes to their positions in the company. Royce & Associates LP raised its position in shares of Bioventus by 15.6% during the third quarter. Royce & Associates LP now owns 1,262,976 shares of the company’s stock worth $8,449,000 after acquiring an additional 170,900 shares during the last quarter. Legato Capital Management LLC raised its position in shares of Bioventus by 1,042.8% during the fourth quarter. Legato Capital Management LLC now owns 137,562 shares of the company’s stock worth $1,023,000 after acquiring an additional 125,525 shares during the last quarter. Hillsdale Investment Management Inc. bought a new stake in shares of Bioventus during the fourth quarter worth $2,008,000. Anderson Financial Strategies LLC raised its position in shares of Bioventus by 58.3% during the fourth quarter. Anderson Financial Strategies LLC now owns 213,208 shares of the company’s stock worth $1,586,000 after acquiring an additional 78,488 shares during the last quarter. Finally, Meros Investment Management LP bought a new stake in shares of Bioventus during the fourth quarter worth $2,345,000. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.